BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%

TORONTO, ONTARIO--(Marketwired - Aug. 12, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Second Quarter (Q2 2015) and first half financial results for the three and six months ending June 30, 2015. Key highlights include:

• First six months (H1 2015) Sales of $6,900,098 increased by 25% versus H1 2014
• H1 2015 Pharma sales of $6,565,300 increased by 25% versus H1 2014
• First six months (H1 2015) Revenue has grown at a compound annual growth rate (CAGR) of 44% over the corresponding previous two years
• H1 2015 EBITDA¹ of $2,490,429 increased by 31% over H1 2014
• H1 2015 Net Income After Tax of $1,813,751 increased by 30% over H1 2014
• H1 2015 Fully Diluted EPS of $0.13 grew by 30% over H1 2014
• Trailing Twelve Month (TTM) fully diluted EPS of $0.25 was 39% higher than $0.18 in the TTM period ending June 30, 2014
• H1 2015 Return on Equity was 40% annualized
• In Canada, FeraMAX® 150 share of doses increased by more than 18% in the January - May 2015 period versus a year ago ( Source data : IMS Health™ )
• A large international FeraMAX® order representing sales of $627,512 received in the first quarter was postponed to Q3 2015 due to a delay in obtaining necessary importation clearances. Had this order been shipped in H1 2015, H1 2015 sales would have grown by 36% versus H1 2014. This order was shipped in the first week of August 2015
• The Company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada of $1.55MM

Working capital, which is the difference between current assets and current liabilities, increased by 24% from $7,786,460 as at December 31, 2014 to $9,641,260 as at June 30, 2015.

Total Shareholder's Equity increased by 24% from $8,160,092 at December 31, 2014 to $10,087,481 at June 30, 2015.

An international FeraMAX® order of $627,512 received in Q1 2015, originally planned for Q2 2015 shipping, was postponed to Q3 2015 due to delay in obtaining necessary importation clearances. If this order had shipped as originally requested by the customer, H1 2015 sales would have grown by 36% versus H1 2014 and Q2 2015 pharma sales would have been +37% versus Q2 2014. This order has been shipped as of the date of this press release and will have a correspondingly positive effect on Q3 2015 results.

"For the first time, in June and July 2015, the Company's sales exceeded $1.5 million per month for two consective months," commented René Goehrum, President and CEO of BioSyent. "In Canada, in the second quarter both FeraMAX 150® and RepaGyn® had their second consective quarter of record shipments. This was backed up with strong year over year growth for Cathejell™ and FeraMAX Powder®. Additionally with the shipment of our largest FeraMAX® order ever to an overseas customer -- the international pharma business is on track to more than double this year."

The CEO presentation on the Second Quarter of 2015 is available at the following link www.biosyent.com/q2-15/

The Company's Consolidated Financial Statements and Management's Discussion & Analysis will be posted on www.sedar.com on August 12, 2015.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,936,195 shares issued and outstanding.

BioSyent Inc.
Interim Unaudited Consolidated Statement of Comprehensive Income
In Canadian Dollars	Q2 2015	Q2 2014	% Change	H1 2015	H2 2014	% Change
Revenues	3,593,998	3,072,395	17%	6,900,098	5,520,496	25%
EBITDA	1,176,105	1,211,096	-3%	2,490,429	1,897,379	31%
Cost Of Goods Sold	739,045	633,754	17%	1,447,780	1,173,278	23%
Gross Profit	2,854,953	2,438,641	17%	5,452,318	4,347,218	25%
Total Operating Expense	1,680,531	1,218,786	38%	2,957,963	2,439,691	21%
Net Income Before Tax	1,174,422	1,219,855	-4%	2,494,355	1,907,527	31%
EBITDA % to Sales	33%	39%		36%	34%
Tax (including Deferred Tax)	323,383	331,050	NA	680,604	507,301	NA
Net Income After Tax	851,039	888,805	-4%	1,813,751	1,400,226	30%
Net Income After Tax % to Sales	24%	29%		26%	25%

¹ EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards ("IFRS") and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

BIOSYENT INC.
INTERIM UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT	June 30, 2015	December 31, 2014	% Change
ASSETS
Receivables	1,568,546	640,691	145%
Inventory	2,213,698	1,271,910	74%
Prepaid expenses & deposits	136,927	203,532	-33%
Derivative Asset	65,551	142,627	-54%
Short-Term Investments	1,500,000	999,969	50%
Cash & Cash Equivalents	5,976,906	6,989,171	-14%
Current Assets	11,461,628	10,247,900	12%
Equipment	214,692	156,907	37%
Intangible Assets	88,651	66,720	33%
Deferred Tax	166,253	173,380	-4%
TOTAL NON CURRENT ASSETS	$ 469,596	$ 397,007	18%
TOTAL ASSETS	11,931,224	10,644,907	12%
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities	1,820,368	2,461,440	-26%
Deferred Tax Liability	23,375	23,375	0%
Total Equity	10,087,481	8,160,092	24%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	11,931,224	10,644,907	12%